A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular Doses of ETI-204 in Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2014
At a glance
- Drugs Obiltoxaximab (Primary)
- Indications Anthrax
- Focus Adverse reactions; Registrational
- Sponsors EluSys Therapeutics
- 30 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Apr 2014 Planned number of patients changed from 20 to 36 as reported by ClinicalTrials.gov
- 10 Apr 2014 Planned End Date changed from 1 Oct 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.